Literature DB >> 23297823

Diverse mechanisms of AKT pathway activation in human malignancy.

Mitchell Cheung1, Joseph R Testa.   

Abstract

AKT/PKB (Protein Kinase B) are central proteins mediating signals from receptor tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases are involved in a number of important cellular processes including cell proliferation and survival, cell size in response to nutrient availability, tumor invasion/metastasis, and angiogenesis.Various components of the AKT signaling pathway are encoded by tumor suppressor genes and oncogenes whose loss or activation, respectively, plays an important role in tumorigenesis. The growing body of evidence connecting deregulated AKT signaling with sporadic human cancers and inherited cancer predisposition syndromes is discussed. We also highlight new findings regarding the involvement of activating mutations of AKT1, AKT2, and AKT3 in somatic overgrowth disorders: Proteus syndrome, hypoglycemia with hypertrophy, and hemimegalencephaly, respectively. In addition, we review recent literature documenting the various ways the AKT signaling pathway is activated in human cancers and consequences for molecularly targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23297823      PMCID: PMC3678724          DOI: 10.2174/1568009611313030002

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  103 in total

Review 1.  Akt-dependent transformation: there is more to growth than just surviving.

Authors:  David R Plas; Craig B Thompson
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

2.  Proteus syndrome: an update.

Authors:  M Michael Cohen
Journal:  Am J Med Genet C Semin Med Genet       Date:  2005-08-15       Impact factor: 3.908

3.  Role for Akt3/protein kinase Bgamma in attainment of normal brain size.

Authors:  Rachael M Easton; Han Cho; Kristin Roovers; Diana W Shineman; Moshe Mizrahi; Mark S Forman; Virginia M-Y Lee; Matthias Szabolcs; Ron de Jong; Tilman Oltersdorf; Thomas Ludwig; Argiris Efstratiadis; Morris J Birnbaum
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 4.  Activation of AKT kinases in cancer: implications for therapeutic targeting.

Authors:  Alfonso Bellacosa; C Chandra Kumar; Antonio Di Cristofano; Joseph Robert Testa
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

Review 5.  Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.

Authors:  Lionel Larue; Alfonso Bellacosa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 6.  Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.

Authors:  Aristotelis Astrinidis; Elizabeth P Henske
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 7.  The Akt of translational control.

Authors:  Davide Ruggero; Nahum Sonenberg
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

8.  Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.

Authors:  Suzana S Couto; Mei Cao; Paulo C Duarte; Whitney Banach-Petrosky; Shunyou Wang; Peter Romanienko; Hong Wu; Robert D Cardiff; Cory Abate-Shen; Gerald R Cunha
Journal:  Differentiation       Date:  2008-10-16       Impact factor: 3.880

9.  Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53.

Authors:  Sungman Park; Donghwa Kim; Han C Dan; Huihua Chen; Joseph R Testa; Jin Q Cheng
Journal:  J Biol Chem       Date:  2012-02-14       Impact factor: 5.157

10.  Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis.

Authors:  J Liu; H L Weiss; P Rychahou; L N Jackson; B M Evers; T Gao
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

View more
  70 in total

1.  Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.

Authors:  Angela M Gocher; Gissou Azabdaftari; Lindsey M Euscher; Shuhang Dai; Loukia G Karacosta; Thomas F Franke; Arthur M Edelman
Journal:  J Biol Chem       Date:  2017-06-20       Impact factor: 5.157

2.  RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway.

Authors:  Huiyan Niu; Baogang Wu; Yang Peng; Hongfang Jiang; Yi Zhang; Jiahe Wang; Yifei Zhang; Ping He
Journal:  Tumour Biol       Date:  2014-09-30

Review 3.  Organ-Size Regulation in Mammals.

Authors:  Alfredo I Penzo-Méndez; Ben Z Stanger
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-07-17       Impact factor: 10.005

4.  Prediabetes linked to excess glucagon in transgenic mice with pancreatic active AKT1.

Authors:  Toya M Albury-Warren; Veethika Pandey; Lina P Spinel; Michal M Masternak; Deborah A Altomare
Journal:  J Endocrinol       Date:  2015-10-20       Impact factor: 4.286

5.  Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin.

Authors:  Gopalakrishnan Ramakrishnan; Gantulga Davaakhuu; Ludmila Kaplun; Wen-Cheng Chung; Ajay Rana; Azeddine Atfi; Lucio Miele; Guri Tzivion
Journal:  J Biol Chem       Date:  2014-01-20       Impact factor: 5.157

Review 6.  Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses?

Authors:  Corinne Abbadie; Olivier Pluquet; Albin Pourtier
Journal:  Cell Mol Life Sci       Date:  2017-07-13       Impact factor: 9.261

7.  AKT plays a crucial role in gastric cancer.

Authors:  Takamitsu Sasaki; Yuichi Yamashita; Hiroki Kuniyasu
Journal:  Oncol Lett       Date:  2015-05-25       Impact factor: 2.967

Review 8.  Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis.

Authors:  J Jeffery; D Sinha; S Srihari; M Kalimutho; K K Khanna
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  Alternative Activation Mechanisms of Protein Kinase B Trigger Distinct Downstream Signaling Responses.

Authors:  Deborah Balzano; Mohamad-Ali Fawal; Jose V Velázquez; Clara M Santiveri; Joshua Yang; Joaquín Pastor; Ramón Campos-Olivas; Nabil Djouder; Daniel Lietha
Journal:  J Biol Chem       Date:  2015-08-18       Impact factor: 5.157

10.  Selective, potent blockade of the IRE1 and ATF6 pathways by 4-phenylbutyric acid analogues.

Authors:  Hui Zhang; Shotaro Nakajima; Hironori Kato; Liubao Gu; Tatsuya Yoshitomi; Kaoru Nagai; Hideyuki Shinmori; Susumu Kokubo; Masanori Kitamura
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.